Malignant neoplasm of connective and soft tissue of right upper limb, including shoulder
ICD-10 C49.11 is a billable code used to indicate a diagnosis of malignant neoplasm of connective and soft tissue of right upper limb, including shoulder.
C49.11 refers to malignant neoplasms arising from connective and soft tissues in the right upper limb, including the shoulder. These tumors are classified as soft tissue sarcomas, which are rare and can originate from various types of connective tissues such as fat, muscle, nerves, fibrous tissues, blood vessels, and lymphatic tissues. The clinical presentation may include a palpable mass, pain, or functional impairment in the affected limb. Diagnosis typically involves imaging studies such as MRI or CT scans, followed by biopsy for histological confirmation. Grading of soft tissue sarcomas is crucial, as it influences treatment decisions and prognosis. Low-grade tumors tend to be less aggressive, while high-grade tumors are more likely to metastasize. Multidisciplinary management is essential, involving surgical oncologists, medical oncologists, and radiation oncologists to optimize treatment outcomes. Surgical resection is the primary treatment modality, often followed by adjuvant therapies depending on the tumor's grade and stage.
Detailed pathology reports, imaging studies, and treatment plans.
Diagnosis and management of soft tissue sarcomas, including surgical interventions and chemotherapy.
Ensure accurate grading and staging documentation to support treatment decisions.
Comprehensive imaging reports detailing tumor size, location, and characteristics.
Pre-operative imaging for surgical planning and post-operative follow-up.
Clear documentation of imaging findings to support coding and treatment planning.
Used in cases where sarcoma involves breast tissue.
Operative report detailing the procedure and findings.
Oncology specialists must ensure accurate coding of tumor type.
Tumor grading is crucial as it determines the aggressiveness of the cancer and influences treatment decisions. High-grade tumors are more likely to metastasize and may require more aggressive treatment.
